WASHINGTON — The maker of one of the world’s most profitable medicines is exiting the pharmaceutical industry’s two major lobbying organizations next year, just as Washington pledges to crack down on high drug costs.
AbbVie, which for years has fought off competition for its blockbuster autoimmune drug Humira — the world’s top-selling medicine before Pfizer’s Covid-19 vaccine hit the market — has been the target of congressional hearings and legislation aimed at so-called patent thickets that can stall rival products.
But now, AbbVie, which is, on its own, one of the top lobbying spenders in the pharmaceutical industry this year, is exiting both the Biotechnology Innovation Organization and the brand drug lobby PhRMA. AbbVie’s exit was first reported by Politico.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect